Antonio Mastroianni

Antonio Mastroianni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antonio Mastroianni has a total of 243 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safety and Efficacy of Combination Antibiotics and Systemic Immunotherapy as Salvage Therapy for Severe Deep Neck Abscess: A Retrospective Case Series with Observational Analysis

    by Antonio Mastroianni, Roberto Manfredi, Antonio Siniscalchi, Sonia Greco

    Introduction/Objective: Deep Neck Abscess (DNA) is a rapidly progressive softtissue infection with high morbidity and mortality rates, especially in the elderly. The natural course involves the soft tissues of the neck with erosion of major blood vessels. The objective of this monocenter, retrospective case series study with observational analysis was to evaluate the safety and efficacy of low-dose Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) in combination with intravenous antibiotics to improve clinical outcomes and reduce mortality in patients with severe DNAs and sepsis. Methods: Seven immunocompetent patients with confirmed bacterial sepsis and DNAs were evaluated over an 8-year period. Diagnosis was established via Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) and positive cultures. Patients received combination therapy consisting of customized intravenous antibiotics and subcutaneous GM-CSF (10 mcg/kg daily) for 5–7 days, alongside aggressive surgical debridement and supportive care. This study adhered to the CARE guidelines for case series and STROBE guidelines for observational analysis. Results: The addition of GM-CSF to intravenous antibiotics and surgical care was safe and well tolerated. All seven patients achieved full clinical recovery with a 100% survival rate through day 29. No local or systemic complications, subsequent organ dysfunction, or thoracic extension of the infection were reported. Discussion: GM-CSF acts as a potent hematopoietic growth factor that stimulates myeloid lineage proliferation and enhances macrophage phagocytosis and neutrophil microbicidal activity. Its adjunctive use provides a synergistic survival benefit and emergency myelopoiesis to accelerate pathogen clearance in non-neutropenic severe tissue infections. Conclusion: Combining targeted antimicrobial coverage with adjunctive low-dose GM-CSF immunotherapy offers a promising, safe, and effective salvage strategy for severe deep neck abscesses, associated with low complication rates and excellent survival outcomes.

  • Efficacy and Safety of Sequential Combined Immunomodulatory Systemic Therapies Used in the Management of Refractory Cytokine Release Syndrome in Critically Ill Patients with COVID-19

    by Antonio Mastroianni, Luciana Chidichimo, Valeria Vangeli, Giuliana Guadagnino, Lavinia Berardelli, Roberto Manfredi, Antonio Siniscalchi, Sonia Greco

    Introduction/Objective: Severe Coronavirus Disease 2019 (COVID-19) is characterized by systemic hyperinflammation and cytokine storm, a series of clinical conditions caused by excessive immune reactions. Although numerous studies have been conducted on anti-inflammatory treatments for severe COVID-19, no specific recommendations have been made regarding drugs to use in patients with Refractory Cytokine Release Syndrome (CRS) after the use of first-line anticytokine drugs. The objective of this report was to evaluate the efficacy of sequential immunomodulatory therapies in the management of refractory CRS in COVID-19 patients. Methods: From March 2020 to March 2023, 1,025 patients with COVID-19 were admitted to the Infectious and Tropical Diseases ward at the Annunziata Cosenza Hub Hospital in Cosenza, Italy. To determine how many patients with refractory COVID-19-associated CRS were treated with combinedsequential therapy involving tocilizumab, a recombinant humanized anti-Interleukin-6 (IL-6) receptor monoclonal antibody, and baricitinib, a Janus kinase inhibitor, or anakinra, a recombinant human interleukin- 1 receptor antagonist, the electronic medical records of all hospitalized patients with COVID-19 were reviewed. The primary outcome was the incidence of CRS by day 29. Secondary outcomes included in-hospital mortality and 30-day mortality, to assess hospital performance and patient safety. Electronic databases such as MEDLINE, EMBASE, and Cochrane Central were searched through June 30, 2026, for case-series and studies evaluating the efficacy of sequential combined immunomodulatory systemic therapies in the management of refractory CRS in critically ill patients with COVID-19. Results: From January 2021 to December 2023, a total of 25 patients received sequential combined immunomodulatory systemic therapies, including tocilizumab and baricitinib or anakinra, in the management of COVID-19-related CRS. After 72 hours from the introduction of the new anti-cytokine therapy, a significant improvement of respiratory parameters, clinical state, inflammatory markers, and blood counts was observed. All patients survived, and those 5 previously mechanically ventilated patients were extubated. Non-infectious or infectious pulmonary or systemic complications were observed in all patients who underwent sequential combined immunomodulatory systemic therapies. Discussion: The study’s findings suggest that tocilizumab used in sequential combination with baricitinib or anakinra, in conjunction with standard of care treatments, was associated with improved outcomes in critically ill patients with COVID-19 disease and early discharge from the hospital. Conclusion: There is clear rationale for using combined immunomodulatory systemic therapies in critically ill patients who develop refractory CRS. The results of the experience, supported by a review of the current literature, suggest the need for larger-scale studies on sequential and combined systemic immunomodulatory therapies to manage refractory CRS in critically ill patients with COVID-19.

  • Open Access

    Unexpected schistosomiasis presenting as acute appendicitis in a migrant adult

    by Sonia Greco, Valeria Vangeli, Giuliana Guadagnino, Luciana Chidichimo, Lavinia Berardelli, Roberto Manfredi, Simona Di Cesare, Antonio Mastroianni

    Was not provided for this article.

  • Open Access

    Improving prediction of future Mycoplasma pneumoniae epidemics using data-driven transmission models

    by Xu-Sheng Zhang, Semjon Sidorov, Ursula Dalrymple, Hanne-Dorthe Emborg, Søren Anker Uldum, Michael L Beeton, Patrick M Meyer Sauteur, Patrick M Meyer Sauteur, Semjon Sidorov, Sabine Pereyre, et al.

  • Open Access

    SARS-CoV-2 as a cause of fatal intestinal perforation

    by Sonia Greco, Luciana Chidichimo, Lavinia Berardelli, Giuliana Guadagnino, Roberto Manfredi, Valeria Vangeli, Antonio Mastroianni

    Gastrointestinal (GI) perforation in association with COVID-19 is uncommonly reported in the literature. In this study, our goal was to elucidate the possible pathologic role of SARS-CoV-2 on the GI tract in a patient suffering from intestinal perforation. A literature review using PubMed identified 40 additional cases of COVID-19-related GI perforation. Including our case, a total of 41 cases has been described in the literature, 18 of which were fatal. Including our case, in only three cases SARS-CoV-2 RNA was detected in intestinal surgical specimens. The detection of Sars-Cov-2 viral RNA in GI tissue samples has not been adequately standardized, and consistent results are lacking. Regular testing for SARS-CoV-2 in biopsy and surgical specimens would be necessary to establish its true, direct pathological role in the GI manifestations associated with COVID-19, also in those patients with severe illness or on treatments like glucocorticoids and tocilizumab.

  • Journal of neurovirology

    by Antonio Mastroianni, Simone Malagò, Valeria Vangeli, Giuliana Guadagnino, Luciana Chidichimo, Maria Vittoria Mauro, Francesca Greco, Robert Tenuta, Lavinia Berardelli, Antonio Mori, et al.

  • Open Access

    New Advancements in the Field of Leishmaniasis

    by Eva Iniguez, Ana Victoria Ibarra-Meneses, Antonio Mastroianni, Isabel L. Mauricio, Pedro Cecilio

    Leishmaniasis is the term used to characterize a spectrum of human diseases caused by more than 20 different Leishmania parasite species

  • Open Access

    Oritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study

    by Antonio Vena, Laura Mezzogori, Matteo Bassetti, Antonio Mastroianni, Sonia Greco, Valeria Vangeli, Salvador López-Cárdenas, Marina Murillo-Pineda, Sofía de la Villa-Martínez, Agustín Estévez-Prieto, et al.

    Introduction The management of complicated Gram-positive bloodstream infections (cBSI) and infective endocarditis (IE) often requires prolonged intravenous therapy. Transition to oral therapy is frequently unfeasible because of resistance, drug interactions, or adherence concerns, increasing the risk of intravenous-related complications and healthcare burden. The pharmacokinetic profile and spectrum of oritavancin may enable effective treatment and early discharge. This study evaluated its effectiveness, safety, and impact on hospital resource use in patients with cBSI or IE. Methods We conducted a multicenter, retrospective, observational study across eight hospitals in Italy and Spain (April 2023–February 2025). Adult patients with Gram-positive cBSI (persistent/refractory BSI or prosthetic material) or IE (2023 modified Duke criteria) treated with ≥ 1 dose of oritavancin were included. Dosing was determined by the treating physicians. Data on outcomes, adverse events (AEs) and healthcare use were collected from medical records. Patients were followed for at least 6 months. Results Twenty-seven patients were included: 13 (48.1%) cBSI and 14 (51.9%) IE. Median age was 73 years (IQR 65–81); 18 out of 27 (66.7%) were male; Charlson Comorbidity Index 6 (IQR 4–7). In cBSI, oritavancin was first-line in 6/13 (46.2%) and given in multiple doses in 8/13 (61.6%), median of 2 doses (IQR 2–2.5). Clinical success was 100%, with no recurrence or BSI-related mortality. In IE, Staphylococcus aureus was identified in 5 of 14 cases (35.7%), of which 40% were methicillin-resistant. Native valves were involved in 6/14 (42.8%), prosthetic valves in 6/14 (42.8%), cardiac devices in 2/14 (14.3%). Clinical success was achieved in 85.7% of patients with IE (12/14). Two AEs occurred: nausea and a non-fatal acute coronary syndrome in a patient with pre-existing ischemic heart disease. Oritavancin use reduced 369 hospital days with potential savings of approximately €4235 per patient. Conclusions Oritavancin may represent a safe, effective treatment option for selected patients with cBSI or IE, with advantages in outcomes, reduced hospital stay, and cost containment.